Recommendation of the President – Remsima (infliximab)

On 28 February 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 26/2025 on the apprisal of Remsima (infliximab) as part of the B.47 drug program “Treatment of patients with moderate to severe plaque psoriasis (ICD-10 L40.0)”

Publication in Public Information Bulletin (BIP) >>